1.1 The PeritX system is recommended as an option for drainage of treatment-resistant, recurrent malignant peritoneal ascites.
Why the committee made these recommendations
Clinical evidence shows that the PeritX peritoneal catheter drainage system is effective for managing treatment-resistant, recurrent malignant peritoneal ascites. It may improve the quality of life of some people with cancer, by enabling early and frequent treatment of symptoms of ascites in the community, rather than waiting for inpatient treatment. The PeritX system can lead to an estimated cost saving of £1,095 per person compared with inpatient large-volume paracentesis.